Deutschland

DGAP-News: coinIX GmbH & Co. KGaA : Blockchain investor coinIX invests in peaq, a Web3 network for for the Internet of Things

Retrieved on: 
Wednesday, July 6, 2022 - 9:04am
Metaverse, Non-fungible token, CEO, Blockchain-based database, Decentralized finance, EOT, Dapp, DAPP, PEAQ, Trust, Internet of things, Polka dot, Web3, Partnership, Gesellschaft mit beschränkter Haftung, Investment, Limited partnership, Blockchain, News, Entrepreneurship, DGAP, Internet, WKN, Economy, CXC, Cryptocurrency, Security (finance), High-resolution audio

coinIX GmbH & Co. KGaA : Blockchain investor coinIX invests in peaq, a Web3 network for for the Internet of Things

Key Points: 
  • coinIX GmbH & Co. KGaA : Blockchain investor coinIX invests in peaq, a Web3 network for for the Internet of Things
    The issuer is solely responsible for the content of this announcement.
  • Hamburg, July 6th 2022 - The Hamburg based investment company coinIX GmbH & Co. KGaA, which specializes in investments in digital assets and blockchain technology, invests in peaq.
  • In the economy of things, machines will also be able to conclude transactions with other machines.
  • Susanne Fromm, CEO of coinIX: "The Internet of Things has grown at a rapid pace in recent years.

DGAP-News: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225

Retrieved on: 
Wednesday, July 6, 2022 - 9:04am
Eckert, CMC, III, LinkedIn, CGMP, Nuclear medicine, Ratio, Medicine, II, GMP, ISIN, IND, SDAX, Quality control, Radiopharmaceutical, Deutsch, Safety, Twitter, Therapy, Security (finance), Pharmaceutical industry, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225.
  • The agreement covers the development of a validated manufacturing process as well as the GMP-compliant production of clinical investigational products.
  • Ratio Therapeutics will use the newly built GMP suites at the Eckert & Ziegler production site near Boston, MA, USA, from July 2022 for this purpose.
  • As a radiopharmaceutical contract manufacturer, Eckert & Ziegler is able to produce small batches for Phase I, II and III clinical studies and large commercially applicable batch sizes.

DGAP-News: ecotel communication ag: Transfer of usage rights for Internet resources successfully concluded

Retrieved on: 
Wednesday, July 6, 2022 - 9:04am
EPS, Telecommunication, Marketing, Solution, Growth, Sale, West Coast of Vancouver Island Aquatic Management Board, Communication, Vodafone, Tax, Cryptocurrency, Risk management, Group

3.00 expected in the current financial year

Key Points: 
  • 3.00 expected in the current financial year
    ecotel communication ag reports the successful conclusion of the transaction for transfer of usage rights for Internet resources.
  • This resulted in the transfer of about 300,000 Internet resources, which will no longer be needed for business operations in the long term.
  • With the completion of the transfer, ecotel communication ag still has about 750,000 resources, about half of which are currently allocated for operation of the network infrastructure and for customers of the ecotel Group.
  • The ecotel Group (hereinafter ecotel), operating throughout Germany since 1998, specializes in the marketing of IT and telecommunications solutions in various segments.